Home Blog Page 1160

XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication

By
Advertorial Desk
-

– XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea’s National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM).

– In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell lymphoma (DLBCL), and two of these approved indications have been included in the national reimbursement scheme.

SHANGHAI and HONG KONG, March 2, 2026 /PRNewswire/ — Antengene Corporation Limited  (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, announced that South Korea’s National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO® (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) after one prior therapy. The reimbursement has taken effect on March 1, 2026. This marks the second XPOVIO® indication to be approved for reimbursement in South Korea.

As Antengene continues to expand its footprint across the Asia Pacific region, the Company remains committed to improving patient access to its innovative therapies. To date, XPOVIO® has been approved in South Korea for three indications in MM and diffuse large B-cell lymphoma (DLBCL), both major hematological malignancies. Two of these indications have been approved for reimbursement, including XPOVIO® in combination with dexamethasone for the treatment of adult patients with relapsed or refractory MM (R/R MM) who have received at least four prior therapies, as well as the newly reimbursed indication. With expanded reimbursement coverage, XPOVIO® is expected to benefit a broader patient population and further contribute to the management of hematological malignancies in South Korea.

With a novel mechanism of action, XPOVIO® is the world’s first approved orally-available, selective XPO1 inhibitor. XPOVIO® has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). Moving forward, Antengene will continue to pursue broader access for XPOVIO® across APAC markets.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecologic tumors and non-small cell lung cancer), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com

Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis

By
Advertorial Desk
-

SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (“Lynk Pharmaceuticals”), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III clinical trial evaluating zemprocitinib in patients with moderate-to-severe atopic dermatitis (AD). The study met all co-primary and key secondary endpoints, with both dose groups demonstrating highly and statistically significant improvements versus placebo (p < 0.0001), together with a favorable safety and tolerability profile.

The disclosed results represent topline data generated in accordance with the predefined statistical analysis plan. Full study data are undergoing further analysis and will be published at a future date.

This study was a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of zemprocitinib in patients with moderate-to-severe atopic dermatitis. The trial was led by Professor Jianzhong Zhang and Professor Cheng Zhou of Peking University People’s Hospital. A total of 356 patients were randomized in a 1:1:1 ratio to receive zemprocitinib 12 mg, or 24 mg or placebo.

The study had two co-primary endpoints at Week 16; the proportion of patients achieving ≥75% improvement from baseline in Eczema Area and Severity Index (EASI-75); and the proportion of patients achieving a validated Investigator Global Assessment for Atopic Dermatitis score of 0 (clear) or 1 (almost clear), with a ≥2-point improvement from baseline (vIGA-AD 0/1 response). The key secondary endpoint was the proportion of patients achieving a ≥4-point improvement from baseline in Worst Itch Numerical Rating Scale (WI-NRS4) at Week 16.

At Week 16, both zemprocitinib dose groups demonstrated statistically significant superiority over placebo across both co-primary endpoints and the key secondary endpoint:

  • EASI-75: Differences versus placebo were 38.1% (12 mg) and 46.4% (24 mg) (p < 0.0001).
  • vIGA-AD 0/1 response: Improvements over placebo were 30.3% (12 mg) and 31.0% (24 mg) (p < 0.0001).
  • WI-NRS4 response rates were 31.3% (12 mg) and 31.0% (24 mg) higher than placebo at Week 16 (p < 0.0001).

Zemprocitinib also achieved statistically significant improvements across multiple additional secondary endpoints, including EASI-50, EASI-90, SCORAD response rates, Dermatology Life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM) scores, supporting broad clinical benefit in lesion clearance, symptom reduction, and quality-of-life improvement. Notably, zemprocitinib demonstrated a rapid onset of action. Improvement in pruritus was observed as early as Day 1 following initiation of therapy, with statistically significant separation from placebo in WI-NRS response rates, indicating rapid itch relief. Statistically significant improvement in EASI-75 response rates and vIGA-AD 0/1 response rates were also observed by Week 2 in both dose groups, highlighting the treatment’s early efficacy in skin lesion improvement.

Zemprocitinib demonstrated a favorable overall safety and tolerability profile. The majority of treatment-emergent adverse events (TEAEs) were Grade 1–2. The incidence of serious adverse events (SAEs), adverse events of special interest (AESIs), and discontinuations due to adverse events were low and comparable to placebo, with no new safety signals observed. Laboratory findings were consistent with those observed in the Phase III rheumatoid arthritis study. No serious adverse reactions related to decreases in hemoglobin, neutrophils, or lymphocytes were observed and there were no safety concerns associated with elevations in ALT or AST. No dose-dependent differences in the safety profile were observed. Overall, the safety profile was consistent with our prior clinical studies and demonstrated competitive characteristics relative to other reported JAK inhibitors.

Professor Jianzhong Zhang, principal investigator from Peking University People’s Hospital, stated: “Atopic dermatitis is a chronic, relapsing inflammatory and pruritic skin disease that imposes a substantial burden on patients’ quality of life and mental health. In this Phase III study, zemprocitinib demonstrated significant improvements in both skin lesion clearance and itch relief, together with a favorable overall safety profile. We look forward to the potential of zemprocitinib to provide a new oral treatment option for patients with moderate-to-severe atopic dermatitis in China.”

Dr. Yu Wu, Chief Development Officer of Lynk Pharmaceuticals, commented: “The success of this Phase III study reflects the strength of our long-term strategic focus in immunology and inflammation. These results further validate the potential of zemprocitinib across multiple autoimmune indications and reinforce our clinical development capabilities. We remain committed to advancing regulatory submissions with scientific rigor and high-quality standards.”

Dr. Zhao-Kui (ZK) Wan, Founder and Chief Executive Officer of Lynk Pharmaceuticals, added: “We are highly encouraged by these positive Phase III results in atopic dermatitis and sincerely thank the patients, investigators, and our internal and external teams for their dedication and professionalism. Following the successful Phase III study in rheumatoid arthritis, this achievement represents another important milestone for zemprocitinib and further reinforces its positioning as a core asset in our pipeline. The favorable balance of efficacy and safety supports its potential differentiated profile in the competitive JAK landscape.”

About Zemprocitinib

Zemprocitinib is a highly selective, next-generation JAK1 inhibitor with best-in-class potential, being developed for the treatment of rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, and vitiligo. Compared with first-generation, less selective JAK inhibitors, zemprocitinib demonstrates significantly greater selectivity for JAK1, which may translate into desirable efficacy while minimizing off-target adverse effects. Zemprocitinib potently and dose-dependently inhibits multiple inflammation-related signaling pathways mediated by JAK1.

About Lynk Pharmaceuticals

Lynk Pharmaceuticals is a clinical-stage biotechnology company founded by senior drug R&D leaders and executives from Pfizer, Merck, and Johnson & Johnson. The company is dedicated to the discovery and development of innovative therapies for immune and inflammatory diseases. Driven by a commitment to address significant unmet medical needs, Lynk Pharmaceuticals aims to deliver differentiated therapies with global impact. To date, the company has independently or jointly advanced multiple innovative drug candidates and successfully completed numerous clinical studies.

Toku Reports US$34.8 million Revenue in FY2025 as AI Adoption Gains Traction; Underlying Loss Improves

By
Advertorial Desk
-

SINGAPORE, March 2, 2026 /PRNewswire/ — Toku Ltd. (“Toku“, “投酷有限公司” or the “Company”, and together with its subsidiaries, the “Group”), a Singapore-incorporated AI-powered customer experience (CX) platform, is pleased to announce its financial results for the full year ended 31 December 2025 (“FY2025”).

Financial Highlights

Million (US$)

FY2025

FY2024

Change (%)

Revenue

34.8

31.8

9.3

Gross Profit

8.4

8.7

(3.1)

Gross Profit Margin

24.3 %

27.4 %

(3.1)

Net Loss

(9.1)

(5.3)

(72.7)

Adjusted Net Loss

(4.2)

(4.6)

8.5

Commenting on the FY2025 results, Thomas Laboulle, Founder and Chief Executive Officer said, “Completing our IPO while operating with a streamlined team and disciplined capital allocation made this undoubtedly a challenging year. I am incredibly proud that we still delivered 9.3% revenue growth, our strongest Adjusted EBITDA to date, new market expansion, and the early monetisation of our Core AI Suite. These results reflect the resilient growth engine we have built. Looking ahead, our focus turns to scaling AI-driven capabilities, deepening our presence across APAC, and beyond, and strengthening the partnerships that will power our next phase of growth.”

Christian Wong, Chief Financial Officer, added: “The financial results for FY2025 demonstrate that our team can simultaneously manage a complex listing process and deliver meaningful operational improvement. Adjusted EBITDA improved 17.8% to its strongest full-year result, with underlying operating expenses declining 7.5% despite continued geographic expansion. The IPO has been transformative for our capital structure: all convertible instruments have been settled, shareholder loans repaid, and our highest-cost debt facility is scheduled for early retirement in April. With these transitional items behind us, the Group enters FY2026 in its strongest financial position since inception, well placed to convert revenue growth into progressive margin improvement.”

Financial Review

In FY2025, the Group revenue increased 9.3% from US$31.8 million in FY2024 to US$34.8 million in FY2025, extending its multi-year growth trajectory. The increase was primarily driven by higher Usage revenue and continued platform adoption across the Group’s expanding geographic footprint.

Segmental Revenue 

Revenue Stream

FY2025 (US$

million)

FY2024 (US$

million)

Change (%)

Usage

23.9

19.8

21.0

Subscriptions and Licensing  

5.6

5.6

0.6

Professional Services

2.4

3.3

(25.6)

Maintenance and Support

2.6

2.9

(12.2)

Hardware

0.2

0.2

(5.1)

Total

34.8

31.8

9.3

Usage revenue, the Group’s largest revenue stream, increased by 21.0% from US$19.8 million to US$23.9 million in FY2025, accounting for 68.8% of total revenue (FY2024: 62.2%). The growth was supported by the full-year contribution from its Latin American operations, higher traffic volumes from existing APAC customers, and early contributions from new deployments. During FY2025, the Group commenced monetisation of its AI-powered capabilities, with the Core AI Suite gaining customer adoption. While the associated revenue contribution was not yet material, AI-driven usage is expected to contribute progressively as deployments scale from FY2026 onwards.

Subscriptions and Licensing revenue edged higher to US$5.6 million, providing a recurring contracted base. Professional Services revenue declined 25.6% to US$2.4 million (FY2024: US$3.3 million), reflecting the Company’s reduced delivery capacity following workforce optimisation initiatives in 2H2024, as well as delayed project commencements. Despite a smaller workforce, resource utilisation improved year-on-year, underscoring stronger operational discipline and improved efficiency within a streamlined structure. With delivery capacity stabilising and pipeline conversions underway, the segment is positioned for recovery, further supported by the expanding channel partner programme. Maintenance and Support revenue decreased 12.2% to US$2.6 million in the same financial period, primarily due to the completion of certain legacy contracts. Recurring support requirements from new enterprise deployments in APAC, LATAM and the MENA regions, together with the expansion of its channel partner programme, are expected to underpin the Group’s medium-term growth across selected revenue streams. This momentum is reflected in recent developments, including a multi-market European enterprise agreement with a leading on-demand delivery platform.

Gross profit decreased 3.1% to US$8.4 million in FY2025 (FY2024: US$8.7 million), with gross profit margin declining from 27.4% to 24.3% for the fiscal year. The margin contraction was primarily due to a shift in revenue mix, as lower-margin Usage revenue expanded its share of total revenue from 62.2% in FY2024 to 68.8% in FY2025. This was compounded by reduced contributions from higher-margin Professional Services and Maintenance and Support revenue streams during the period.

The Group’s overall gross profit margin levels reflect its strategic positioning as a comprehensive enterprise platform operating across the entire customer experience value chain. While overall margins may be lower than those of pure software providers, this is consistent with the Group’s integrated platform strategy of combining connectivity infrastructure with higher-margin software and services offerings. This approach supports customer retention and provides a foundation for margin improvement as scale increases and higher-margin offerings expand.

The reported EBITDA loss widened to US$8.5 million in FY2025 (FY2024: US$4.4 million), reflecting the inclusion of approximately US$5.3 million in non-cash and non-recurring items, primarily listing costs and accelerated share-based expenses. Excluding these IPO-related items, Adjusted EBITDA improved to a loss of US$3.3 million in FY2025 from a loss of US$4.0 million in FY2024, marking the Group’s strongest full-year EBITDA performance to date. The adjusted EBITDA margin improved by 3.2 percentage points from (12.6%) in FY2024 to (9.4%) in FY2025, driven by revenue growth and operating expense discipline, reflecting improving operating leverage as the Group scales.

Interest expense increased to US$0.8 million due to higher average borrowings during the year. The Group’s venture debt facility with IRIS Fund LP is scheduled for early repayment on 9 April 2026, which is expected to eliminate the associated interest costs. Following the IPO, all convertible instruments have been converted into equity and shareholder loans repaid, resulting in a simplified capital structure.

As such, net loss for FY2025 was US$9.1 million (FY2024: US$5.3 million), largely attributable to approximately US$4.9 million of non-cash and non-recurring items recognised predominantly in Q4 2025 in connection with the IPO. These comprised fair-value adjustments on pre-IPO redeemable convertible loans, listing-related professional and regulatory fees, and accelerated share-based payment charges arising from the settlement of the employee share option plan.

Excluding these non-recurring and non-cash items, as well as the non-recurring deferred tax credit recognised during the year, Adjusted Net Loss improved by 8.5% to US$4.2 million in FY2025 (FY2024: US$4.6 million). The Adjusted Net Loss margin improved from (14.5%) to (12.1%) in the respective periods, reflecting revenue growth and operating cost discipline.

Business Outlook

The Group enters FY2026 with a simplified capital structure, improving operational momentum, and several catalysts for growth, particularly across APAC and the Middle East and North Africa (MENA) markets. Management expects AI-driven usage to contribute progressively to revenue as the Core AI Suite and Agentic AI programme move into broader production deployment. The expanding channel partner programme is anticipated to accelerate Subscriptions and Licensing growth, while Professional Services is positioned for recovery as delivery capacity stabilises and partner-delivered engagements complement direct delivery.

Margin improvement remains a key management priority. The revenue mix is expected to shift gradually towards higher-margin software and AI-enhanced services, while the transition to a channel partner-led distribution model is designed to enable the Group to scale without proportional cost increases. The Group anticipates higher recurring compliance and marketing costs in FY2026 as a newly listed entity, though these are expected to be progressively absorbed as operating leverage builds.

With pre-IPO transitional items behind it and its highest-cost borrowing facility scheduled for early retirement, the Group is well positioned to pursue its medium-term profitability objective while continuing to expand across APAC, LATAM, and the MENA region.

Over the next 12 months, the Group’s performance may be affected by factors such as the pace of AI adoption and monetisation at scale, the expansion of the channel partner programme, and the execution of potential strategic acquisitions. This may also be further influenced by competitive pricing dynamics in traditional connectivity services, macroeconomic conditions in key markets the Group operates in, and foreign exchange movements.

—END—

About Toku

Headquartered in Singapore, Toku Ltd. (“Toku“) is a cloud-native, AI-powered customer experience platform purpose-built for enterprises operating in complex, multi-market environments. With deep roots in the APAC region and an expanding global footprint, Toku’s modular 360° CX Platform orchestrates customer interactions across voice, chat, email and digital channels while managing regulatory, linguistic and infrastructure complexity at scale.

Built on end-to-end ownership of its technology stack, from carrier-grade connectivity to AI applications, Toku delivers enterprise-grade security, reliability and deployment flexibility across commercial cloud, private data centres and hybrid environments. Its AI capabilities include transcription, summarisation, sentiment analysis, conversation analytics and governed virtual agents, designed to integrate seamlessly with enterprise systems and customer data.

Trusted by leading enterprises and public-sector organisations, Toku helps organisations streamline operations, scale customer engagement and deliver consistent experiences across fragmented markets.

For more information about Toku, visit toku.co

Toku Ltd. (the “Company“) was listed on Catalist of the Singapore Exchange Securities Trading Limited (the “Exchange“) on 22 January 2026. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor“).

This press release has been reviewed by the Sponsor. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. 

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

 

Understanding China’s whole-process people’s democracy

By
Advertorial Desk
-

BEIJING, March 2, 2026 /PRNewswire/ — A report from People’s Daily: The upcoming “two sessions,” the annual meetings of China’s top legislature, the National People’s Congress (NPC), and the top political advisory body, the National Committee of the Chinese People’s Political Consultative Conference (CPPCC), provide an important opportunity to observe Chinese modernization and a key window into understanding whole-process people’s democracy in China.

As an original and defining concept, whole-process people’s democracy is deeply embedded in the daily lives of the Chinese people.

Deliberating the draft outline of the 15th Five-Year Plan (2026-2030) is a major focus of this year’s “two sessions.” The process of formulating the plan itself is a vivid practice of whole-process people’s democracy.

From May 20 to June 20, 2025, an online public consultation was conducted for the formulation of the 15th Five-Year Plan. The initiative drew over 3.11 million valid submissions, yielding more than 1,500 constructive suggestions across 27 topics.

The drafting group attached great importance to these inputs, carefully studied and incorporated them, with many reflected in relevant policy measures of the plan in appropriate forms.

By the end of 2025, the Legislative Affairs Commission of the NPC Standing Committee had established 60 grassroots legislative outreach offices, which in turn drove the establishment of more than 7,800 such offices at the provincial and municipal levels. In 2025, more than 1,400 CPPCC members submitted over 12,000 reports on public sentiment. These diverse channels for reflecting public opinion serve as important bridges linking the people with the authorities.

Such democracy widely participated by the people has made “micro-governance” more dynamic and efficient.

At a “People’s Livelihood Teahouse” in Wenhe subdistrict, Guangling district, Yangzhou, east China’s Jiangsu province, deputies to people’s congresses at various levels, members of CPPCC local committees, and local residents gather to discuss issues affecting people’s livelihoods. There, residents’ concerns are addressed, and some suggestions are promptly relayed to relevant authorities.

In recent years, similar platforms have been established one after another, making primary-level governance smoother and more effective.

From farmlands and factory floors to hospitals, schools, and communities, NPC deputies and CPPCC members diligently perform their duties, soliciting opinions from the public, and turning suggestions into concrete actions that deliver tangible benefits.

In 2025, all 269 motions and 9,160 suggestions submitted by NPC deputies were reviewed and handled, with responses provided to the deputies. Of the more than 5,900 proposals submitted by CPPCC members, over 5,000 were filed, and some suggestions were incorporated into relevant policy documents.

A defining feature of “whole-process” is that it runs through the entire chain, spans all dimensions, and covers all areas.

Take food safety, a matter of widespread public concern, as an example. From May to September 2025, the NPC Standing Committee’s law enforcement inspection team carried out inspections on the implementation of the Food Safety Law.

The team placed great emphasis on hearing public voices, incorporating public opinion, and pooling public wisdom.

Two deputies who led relevant motions and 10 other deputies were invited to participate throughout the process, contributing professional expertise and offering suggestions from different perspectives on strengthening food safety.

The team also organized a questionnaire survey on the implementation of the law, collecting 488,200 valid responses and 119,800 public suggestions.

During the inspection, the NPC Standing Committee also completed targeted amendments to the Food Safety Law. By integrating legislative and oversight functions, it further urged localities and departments to fulfill their responsibilities, improved relevant laws, regulations, and standards systems, strengthened law enforcement capacity, and consolidated a social governance framework for food safety, collectively safeguarding public health.

Whole-process people’s democracy is not occasional, partial, fragmented, or piecemeal. Rather, it runs through the entire chain of democratic election, consultation, decision-making, management, and oversight; spans all aspects of political and social life; and covers all fields, including economic, political, cultural, social, and ecological development.

Continuously meeting the people’s growing needs for a better life is an inherent requirement of developing democracy. Democracy is meant to solve the problems for the people.

China’s development demonstrates that only a democracy suited to a country’s specific conditions can be reliable and effective. The defining features of “whole-process” people’s democracy enrich the forms of human political civilization and offer a Chinese approach to exploring better social systems.

Looking ahead, China will continue to follow a path of democratic development suited to its national conditions, advocate and support other countries in independently choosing their own paths of democratic development, and work together to advance the progress of democracy for all humanity.

Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

By
Advertorial Desk
-

SAN FRANCISCO and SUZHOU, China, March 2, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces the non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, Jaypirca® (pirtobrutinib), has received approval by the National Medical Products Administration (NMPA) in China for a new indication for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) after at least one line of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.

Pirtobrutinib is a highly selective kinase inhibitor that utilizes a novel non-covalent binding mechanism to extend the benefit of targeting the BTK pathway in CLL/SLL patients previously treated with a covalent BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib).[1],[2] Pirtobrutinib received approval from the U.S. FDA in January 2023 as a non‑covalent (reversible) BTK inhibitor. In October 2024, pirtobrutinib was approved in China as a monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two prior systemic therapies, including a Bruton’s tyrosine kinase (BTK) inhibitor.

The approval of this new indication is based on results from the international, multicenter, randomized, Phase 3 BRUIN CLL‑321 study. BRUIN CLL‑321 is the world’s first randomized Phase 3 trial conducted in patients with CLL/SLL who had previously been treated with a covalent BTK inhibitor (cBTKi). The study enrolled a total of 238 patients and evaluated the efficacy and safety of pirtobrutinib monotherapy versus investigator’s choice of IdelaR (idelalisib plus rituximab) or BR (bendamustine plus rituximab). The results demonstrated that pirtobrutinib significantly prolonged median progression‑free survival (PFS) compared with the investigator’s choice regimen (14.0 months vs 8.7 months; hazard ratio [HR] = 0.54). In addition, the discontinuation rate due to treatment‑related adverse events was lower with pirtobrutinib (5.2% vs 21.1%), further supporting its efficacy and tolerability advantages in patients previously treated with a covalent BTK inhibitor.[3]

Professor Lu-Gui Qiu, Principal Investigator of the BRUIN CLL‑321 study in China, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, stated, “BTK inhibitors have become the preferred first‑ or second‑line treatment for patients with CLL/SLL, yet some patients still experience disease progression and have a poor prognosis. Studies have shown that the median overall survival for patients after discontinuing a covalent BTK inhibitor is only about 22.7 months.[4] Therefore, there is an urgent clinical need for new treatment. As a next‑generation, non‑covalent and reversible BTK inhibitor, pirtobrutinib represents an important advancement for patients with relapsed or refractory CLL. The BRUIN CLL‑321 study demonstrated its therapeutic potential in CLL/SLL. We believe it will offer an important treatment option for patients with CLL/SLL in China and help meet the needs of long‑term disease management in the future.”

Dr. Li Wang, Lilly Corporate Senior Vice President, Head of Lilly China Drug Development & Medical Affairs Center, states, “The approval of pirtobrutinib for the CLL/SLL indication in China marks an important milestone in the treatment journey for Chinese CLL/SLL patients. It means that patients who continue to experience disease progression after covalent BTK inhibitor therapy can now gain timely access to this globally innovative treatment option. Supported by the efficacy and safety demonstrated in the BRUIN CLL‑321 study, we are pleased to offer a new therapeutic choice for CLL/SLL patient population with significant unmet medical needs in China. Looking ahead, Lilly will remain committed to accelerating the introduction of cutting‑edge therapies to help patients with hematologic malignancies in China achieve longer and better quality of survival. This is our enduring commitment to patients in China.”

Dr. Hui Zhou, Chief R&D Officer of Oncology in Innovent, stated, “Jaypirca (pirtobrutinib) is a next-generation, non-covalent (reversible) BTK inhibitor. It offers a novel treatment option for patients who have previously received covalent BTK inhibitor therapy. The approval in China for CLL/SLL represents a significant breakthrough in this field, which ensures that CLL/SLL patients in China have timely access to this global therapeutic innovation. We will fully leverage Innovent’s leading brand presence and commercialization capabilities in oncology, to accelerate the accessibility of this innovative therapy, thereby benefiting more cancer patients in need.”

About BRUIN CLL-321
BRUIN CLL-321 is a Phase 3, randomized, open-label study of Jaypirca versus investigator’s choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in covalent Bruton tyrosine kinase (BTK) inhibitor pre-treated patients with relapsed and refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The trial enrolled 238 patients, who were randomized 1:1 to receive Jaypirca (200 mg orally, once daily) or investigator’s choice of either IdelaR or BR per labeled doses. This trial’s primary endpoint is progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria, as assessed by blinded independent review committee (IRC). Secondary endpoints include PFS, as assessed by investigator; overall response rate (ORR) and duration of response (DoR); event-free survival; overall survival (OS) and time to next treatment (TTNT); safety and tolerability; and patient-reported outcomes (PRO).  

About Jaypirca (pirtobrutinib)
Jaypirca (pirtobrutinib, formerly known as LOXO-305) (pronounced jay-pihr-kaa) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), non-covalent (reversible) inhibitor of the enzyme BTK.[2] BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).[5],[6]

In China, pirtobrutinib was developed by Eli Lilly and Company and is commercialized in mainland China by Innovent Biologics.

About Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are forms of slow-growing non-Hodgkin lymphoma that develop from white blood cells known as lymphocytes.[7] In China, chronic lymphocytic leukemia (CLL) represents approximately 6%–7% of non-Hodgkin lymphoma cases.[8] SLL is identical to CLL from a pathologic and immunophenotypic standpoint, with the main difference between them being the location of the cancer cells. In CLL, the cancer cells are present in the blood, and in SLL, the cancer cells are found in the lymph nodes.[7]

About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

  1. Jaypirca. Prescribing Information. Lilly USA, LLC.
  2. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892-901. doi:10.1016/S0140-6736(21)00224-5
  3. Sharman JP,et al.2024 ASH Oral presentation #886
  4. Woyach JA, Ruppert AS, Guinn D, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437-1443. doi:10.1200/JCO.2016.70.2282
  5. Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186/s13045-020-00914-1
  6. Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40. Published 2021 Mar 6. doi:10.1186/s13045-021-01049-7
  7. Mukkamalla SKR, Taneja A, Malipeddi D, et al. Chronic Lymphocytic Leukemia. [Updated Feb 18, 2023]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433
  8. CACA. 中国肿瘤整合诊治指南（CACA）- 白血病 2022.

 

Investor Education Webinar

By
Advertorial Desk
-

The Future of Prostate Imaging: What do physicians want?

MELBOURNE, Australia and INDIANAPOLIS, March 2, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) invites investors to join a webinar with key opinion leaders to discuss a physician’s perspective on innovations in PSMA-PET/CT imaging for prostate cancer.

Speakers:

  • Rodney Hicks, MD, Professor of Medicine at the University of Melbourne and Monash University; Founder, Executive Chairman and Chief Medical Officer at the Melbourne Theranostic Innovation Centre (MTIC);  
  • Paul Yonover, MD, FACS, Chief Data Officer and Director of Clinical Navigation at UroPartners, a division of The Specialty Alliance; Chief of Urology at Ascension Saint Joseph Hospital, Chicago; and
  • Darren Patti, PharmD, Telix Group Chief Operating Officer.

The webinar will be moderated by David N. Cade, MD, Telix Group Chief Medical Officer.

The webinar will be held on:

EST: Wednesday March 4, 2026, 5:30 p.m.
AEDT: Thursday March 5, 2026, 9:30 a.m.
The event will run for approximately one hour.

Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/n87mam6r

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)

Ms. Kyahn Williamson

SVP Investor Relations and Corporate Communications

kyahn.williamson@telixpharma.com

Telix Investor Relations (Australia)

Ms. Charlene Jaw

Associate Director Investor

Relations

charlene.jaw@telixpharma.com

Telix Investor Relations (U.S.)  

Ms. Annie Kasparian  

Director Investor Relations and Corporate Communications  

annie.kasparian@telixpharma.com 

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Trip.com’s Go Explore Mega Sale Set to Launch – Save on Flights, Hotels, Tours & More

By
Advertorial Desk
-

SYDNEY, March 2, 2026 /PRNewswire/ — Trip.com’s Go Explore Mega Sale is set to take off, bringing massive savings to travellers across flights, hotels, attractions, eSIMs, car hire, airport transfers and trains.


Customers can subscribe to deals now via the Trip.com website and mobile app ahead of the main drop on Tuesday, 3 March, when exclusive offers will be released at various times throughout the day.

Exclusive Discounts with China Eastern


Trip.com is fuelling your jet-setting adventures with irresistible deals with China Eastern Airlines. On March 3, snag promo codes that get you $100 off return flights from Australia, and $50 off one-way flights from Australia, when you fly with China Eastern Airlines.

Huge Flight Savings: Domestic & International Fares From $29

Beyond exclusive airline offers, travellers can unlock up to 50% off flights with promo codes (capped at $100), alongside up to $40 off domestic flights (minimum spend $135), perfect for spontaneous weekends away or locking in early Easter escapes.

Select international carriers will also feature promo codes offering up to $100 off, helping those stretch their travel budget further.

Flight Flash Sale promises standout fares. Domestic routes to and from Sydney, Melbourne, Brisbane and Adelaide will be available from just $29, while sunseekers can jet from Perth to Bali from $109. Travellers dreaming of vibrant street food and culture can also secure fares from Sydney, Melbourne and Brisbane to Ho Chi Minh City from $149.

Hotel Deals: Up to 70% Off Global Stays

Whether planning a domestic city break or an overseas adventure, travellers can secure quality stays at exceptional value.


Trip.com is also unlocking major accommodation deals worldwide, with up to 50% off hotel promo codes (capped at $100) and discounts of up to 70% off hotels across the globe.

A dedicated Hotel Flash Sale will spotlight 4-star stays in China, Thailand, Japan and Bali from just $29 per night, giving travellers even more reason to turn their summer daydreams into confirmed bookings.

Attractions, & Tours eSIMs: Explore for Less

Holidaymakers can enjoy 50% off eSIMs, making it easier and more affordable to stay connected overseas, as well as 50% off and Buy 1 Get 1 Free deals on attractions and tours across Australia, Southeast Asia, China, and beyond. From bucket-list landmarks to family-friendly experiences, travellers can explore more while spending less.

Car Hire, Airport Transfers & Rail

Rounding out the campaign are savings on essential transport options that make seamless travel planning even easier. Customers can enjoy 50% off car hire, up to 20% off airport transfers, and up to 50% off high-speed train tickets in China, Europe and Japan — ideal for multi-city itineraries and cross-border adventures.

Subscribe Now, Save More on 3 March

All deals can be subscribed to ahead of 3 March, when discounts will be released in stages throughout the day.

Deals are available exclusively via Trip.com during the campaign period, subject to availability and terms and conditions. Promotions are available on a first-come, first-served basis during the specified period and while stocks last.

Visit the Go Explore Mega Sale and start saving with Trip.com.

About Trip.com

Trip.com is an international one-stop travel service provider, available in 24 languages across 39 countries and regions in 35 local currencies. Trip.com has an extensive hotel and flight network consisting of more than 1.7 million hotels and flights from over 600 airlines covering 3,400 airports in 220 countries and regions around the globe. Trip.com’s world-class 24/7 multilingual customer service, as well as additional centres in Edinburgh, Tokyo and Seoul, help to ‘create the best travel experience’ for its millions of customers worldwide. To book your next trip, visit Trip.com.

 

Say Hello to Speed: The Baseus PicoGo AM52 Qi2.2 Magnetic Power Bank Slim

By
Advertorial Desk
-

SHENZHEN, China, March 1, 2026 /PRNewswire/ — At Baseus, the commitment to user needs shines through in every product design. With values that focus on innovation and versatile lifestyles, Baseus prioritizes original, minimalistic, and efficient engineering that makes life simpler, safer, and better. Now, Baseus is proud to be expanding its PicoGo MagSafe range with the sleek new Baseus PicoGo AM52 Qi2.2 Magnetic Power Bank Slim.

Baseus PicoGo MagSafe Family
Baseus PicoGo MagSafe Family

This flagship power bank takes the spotlight in the new Baseus slim, safe, and fast charging era, and is one of the thinnest Qi2.2 magnetic power banks available, delivering 25W safe wireless charging. The AM52 power bank comes in two models, both with and without an integrated cable, for versatile and expanded charging options.

The PicoGo series was designed to be durable, fast, and effective, with certain products that have triple cooling systems, TÜV-certified safety, and other unique features. More than anything, the PicoGo series positions itself as the preferred and most trusted charging choice for all iPhone users. For now, let’s look at some of the main highlights the AM52 has to offer.

Baseus PicoGo AM52 Qi2.2 Magnetic Power Bank Slim

Designed Compact: The Baseus PicoGo AM52 Qi2.2 Magnetic Power Bank was built to be slim and easy to carry around. Weighing just 6.95 oz, which is only 1.2 times the weight of the iPhone 17 Air, the power bank remains effortlessly portable, wherever you choose to go. With a durable, all-day 10,000 mAh battery life and airline-friendly design, the lightweight AM52 is the ideal companion on every journey.

Qi2.2-Certified Fast Charging: Baseus was one of the brands to bring Qi2 25W charging to the market after its launch in 2025, ensuring improved wireless charging. Now, the AM52 power bank offers Qi2.2 25W wireless charging with Magnetic Power Profile alignment for faster efficiency, reduced heat, and safer charging that won’t compromise battery health. You can also choose 45W full-speed wired charging through the USB-C cable, or recharge the power bank itself at 30W, with enough juice to fully power up its 10,000 mAh Apple MagSafe battery pack in just 1.5 hours.

Versatile Charging Options: The AM52 easily supports dual MagSafe and USB-C simultaneous fast charging as well. Choosing the integrated cable AM52 model allows you to charge three devices simultaneously, with wireless charging for AirPods and wired charging for a phone and another low-powered device. Without the built-in cable, you still get a 30cm USB-C to USB-C cable that allows you to charge two devices at the same time, with wireless charging for AirPods and wired charging for a phone.

Elevated for the iPhone Crowd: The AM52 power bank was designed primarily for iPhone users who value minimalist design and efficient living. Focused on creating a lightweight, portable powerhouse solution, the AM52 effortlessly solves the problem of bulky chargers and inconvenient charging hassles during every journey, whether it’s across the world, to the coffee shop, or simply on the way to work each day. The power bank easily pushes an iPhone 17 Pro up to 45% in just 30 minutes.

Safer Thermal Control: Heat is one of the most critical issues for many power banks. Fortunately, the AM52 ensures advanced thermal control with triple-loop cooling that allows you to keep the surface temperature below 102°F (39°C), which is 12% cooler than most traditional Qi2.2 power banks and far below the industry standard of 118.4°F (48°C). With NTC smart temperature control safety, graphene-layered cooling, and an aluminum alloy shell, the AM52 provides secure and efficient heat dissipation settings.

Built to Be Comfortable: To maintain a comfortable and premium look, the AM52 power bank was crafted with curved edges that contour naturally to your grip, a soft silicone front for scratch, fingerprint, and slip resistance, and an aluminum alloy back for enhanced durability and a sleek aesthetic. The thinner body also makes it easier to hold, while the 16 upgraded N52 magnets ensure a stronger, more precise magnetic hold that instantly locks into place for stable charging, even on the go.

The Baseus PicoGo series was designed to make life easier, with rapid fast charging, advanced heat control, and reliable safety and durability. The AM52 provides a new flagship to look up to as the pinnacle of slim, Qi2.2-certified fast charging perfection. As always, the Baseus mission relies entirely on the satisfaction of users and the pursuit of excellence, a cause that the AM52 certainly delivers on.

Availability

  • The Baseus PicoGo AM52 Qi2.2 Magnetic Power Bank Slim is now available on the U.S., German and UK Amazon pages at the recommended price of $69.99, €69.99 and £59.99. It is also available on Amazon Italy, France and Spain at a recommended retail price of €69.99. 
  • The Baseus PicoGo AM52 Qi2.2 Magnetic Power Bank Slim + Cable is also now available on U.S. and UK Amazon pages at a recommended prices of $79.99 and £69.99. The German, Italian, French and Spanish Amazon listings will be available starting mid-March, with a recommended retail price of €79.99.

 

1...1,1591,1601,161...6,714Page 1,160 of 6,714